ArticleCommunications biology2025
Lactoferrin-osteopontin complexes: insights into intestinal organoid bioavailability and gut microbiota modulation.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Effects of Dietary Lactoferrin-Osteopontin Complexes on Immune Function, Intestinal Health and Microbiota Composition in Kittens.Veterinary sciences · 2026Article
- Lactopontin in a Simulated Infant Formula Protein Matrix Promotes Bone Development via the Gut-Bone Axis in Growing Rats.Nutrients · 2026Article
- Optimizing Lactoferrin Isolation for Functional and Structural Integrity: A Molecular Insight.Molecules (Basel, Switzerland) · 2026Review
- Special Issue "New Insights into Lactoferrin".International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lactoferrin (LF) and osteopontin (OPN) are key bioactive milk proteins with significant immune-modulatory, gut, and systemic health benefits. We investigated the bioavailability and intestinal uptake dynamics of bovine LF-OPN soluble complexes (SC) and complex coacervates (CC) using a microarrayed high-throughput 3D apical-out intestinal organoid platform, which closely mimics the human intestinal epithelium. Our findings revealed that both SC and CC complexes exhibited cellular uptake compared to individual LF and OPN components. Nevertheless, complexation did not compromise intestinal organoid viability, even following extended exposure. Further, an ex vivo bioreactor-based colon fermentation study using infant fecal microbiota demonstrated that LF-OPN complexes significantly influenced microbial metabolic activities. This modulation leads to enhanced production of short-chain fatty acids (SCFAs), particularly elevating butyrate levels, a key metabolite for sustaining gut health. The phylogenetic analysis highlighted significant shifts in microbial composition, favoring beneficial bacterial families such as Bacteroides fragilis, Phocaeicola dorei, Parabacteroides spp., and Clostridium symbiosum for complex bioactives. Our findings indicate that LF-OPN complexes have significant potential to further optimize infant nutrition by enhancing the bioavailability of bioactive compounds and promoting gut health through microbiota modulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.